ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS |
NOTE 21:-
|
ADDITIONAL
INFORMATION TO THE ITEMS OF PROFIT OR LOSS |
|
| |
Year
ended December 31, | |
|
| |
2024 | | |
2023 | | |
2022 | |
a. |
Research and development expenses: | |
| | |
| | |
| |
|
Wages and related expenses | |
$ | 390 | | |
$ | 392 | | |
$ | 436 | |
|
Share-based payment | |
| 45 | | |
| 34 | | |
| 264 | |
|
Regulatory, professional and other expenses | |
| 681 | | |
| 719 | | |
| 750 | |
|
Research and preclinical studies | |
| 211 | | |
| 101 | | |
| 703 | |
|
Clinical studies | |
| 276 | | |
| 254 | | |
| 369 | |
|
Chemistry and formulations | |
| 104 | | |
| 141 | | |
| 281 | |
|
| |
| | | |
| | | |
| | |
|
| |
| 1,707 | | |
| 1,641 | | |
| 2,803 | |
|
| |
| | | |
| | | |
| | |
b. |
Sales and marketing expenses: | |
| | | |
| | | |
| | |
|
Advertising | |
$ | 367 | | |
$ | 576 | | |
$ | 363 | |
|
Amazon fees | |
| 495 | | |
| 1,042 | * | |
| 454 | * |
|
Depreciation | |
| 366 | | |
| 486 | | |
| 144 | |
|
Storage and shipping | |
| 167 | | |
| 145 | * | |
| 91 | * |
|
Management fees | |
| 120 | | |
| 235 | | |
| 30 | |
|
| |
| | | |
| | | |
| | |
|
| |
| 1,515 | | |
| 2,484 | | |
| 1,082 | |
|
| |
| | | |
| | | |
| | |
c. |
General and administrative
expenses: | |
| | | |
| | | |
| | |
|
Wages and related expenses | |
| 507 | | |
| 415 | | |
| 437 | |
|
Share-based payment | |
| 419 | | |
| 68 | | |
| 633 | |
|
Professional and directors’ fees | |
| 3,009 | | |
| 2,594 | | |
| 2,468 | |
|
Business development expenses | |
| 108 | | |
| 86 | | |
| 161 | |
|
Regulatory expenses | |
| 158 | | |
| 202 | | |
| 162 | |
|
Office maintenance, rent and other expenses | |
| 128 | | |
| 110 | | |
| 80 | |
|
Investor relations and business expenses | |
| 197 | | |
| 369 | | |
| 1,486 | |
|
| |
| | | |
| | | |
| | |
|
| |
| 4,526 | | |
| 3,844 | * | |
| 5,427 | |
|
| |
| | | |
| | | |
| | |
d. |
Other expenses (income): | |
| | | |
| | | |
| | |
|
Loss from sale of property and equipment | |
| 17 | | |
| - | | |
| - | |
|
Gain on sale of patent license, net
(net of Polyrizon Ltd. holdings sold) (See also Note 25b) | |
| (1,287 | ) | |
| - | | |
| - | |
|
| |
| (1,270 | ) | |
| - | | |
| - | |
|
| |
| | | |
| | | |
| | |
e. |
Finance income: | |
| | | |
| | | |
| | |
|
Net change in fair value of financial liabilities designated
at fair value through profit or loss | |
| (191 | ) | |
| (2,205 | ) | |
| (7,832 | ) |
|
Interest from loans to related parties and deposits | |
| (421 | ) | |
| - | | |
| - | |
|
Exchange rate differences, net | |
| - | | |
| (14 | ) | |
| - | |
|
| |
| | | |
| | | |
| | |
|
| |
| (612 | ) | |
| (2,219 | ) | |
| (7,832 | ) |
f. |
Finance expenses: | |
| | | |
| | | |
| | |
|
Issuance expenses related to warrants | |
| - | | |
| - | | |
| 1,204 | |
|
Exchange rate differences, net | |
| 18 | | |
| - | | |
| 4 | |
|
Losses from remeasurement of investment in financial assets | |
| 305 | | |
| 1,046 | | |
| 770 | |
|
Finance expense in respect of leases | |
| 8 | | |
| 9 | | |
| 15 | |
|
Finance expenses from interest and
commissions | |
| 22 | | |
| - | | |
| 21 | |
|
| |
| | | |
| | | |
| | |
|
| |
$ | 353 | | |
$ | 1,055 | | |
$ | 2,014 | |
|